PCR detection and typing of human papilloma virus DNA in squamous carcinoma of the cervix in a cohort of Sri Lankan women

Silva, Rajiva de; Karunarathne, K; Mendis, L; Ramesh, Ramya; Chow, Vtk

doi:10.4038/cmj.v51i3.1255

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of HPV-16 reported in this study was lower when compared to other studies in Sri Lankan women with invasive SCC (74%–77%) [13,15], but higher than that reported from a worldwide surveillance study by Sanjose et al (61%) [16]. On the other hand, the prevalence of HPV-18 in this study was lower when compared to that reported by de Silva et al (20%) [15] and Sanjose et al (10%) [16] but higher than that reported in a study by Samarawickrema et al (6.5%) [13]. This highlights the need for a vaccine which offers broader protection, irrespective of type, as non-HPV-16/-18 lesions may play a substantial role in the local disease burden [17].…”

Section: Discussioncontrasting

confidence: 85%

“…This corresponds to worldwide estimates of approximately 70% of ICC cases which are caused by these HPV types [1,3]. The prevalence of HPV-16 reported in this study was lower when compared to other studies in Sri Lankan women with invasive SCC (74%–77%) [13,15], but higher than that reported from a worldwide surveillance study by Sanjose et al (61%) [16]. On the other hand, the prevalence of HPV-18 in this study was lower when compared to that reported by de Silva et al (20%) [15] and Sanjose et al (10%) [16] but higher than that reported in a study by Samarawickrema et al (6.5%) [13].…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka

et al. 2014

View full text Add to dashboard Cite

BackgroundCervical cancer ranks second among all cancers reported in Sri Lankan women. This study assessed the prevalence and type-distribution of human papillomavirus (HPV) among Sri Lankan women with invasive cervical cancer (ICC) and pre-cancerous lesions.Methods114 women aged 21 years and above, hospitalized in the National Cancer Institute, Sri Lanka with a diagnosis of ICC or cervical intraepithelial neoplasia (CIN) 2/3 were prospectively enrolled between October 2009 and September 2010 (110430/NCT01221987). The cervical biopsy or excision specimens collected during routine clinical procedures were subjected to histopathological review. DNA was extracted from samples with a confirmed histological diagnosis and was amplified using polymerase chain reaction and HPV DNA was detected using Enzyme Immuno Assay. HPV positive samples were typed using reverse hybridization Line Probe Assay.ResultsOf the cervical samples collected, 93.0% (106/114) had a histologically confirmed diagnosis of either ICC (98/106) or CIN 2/3 (8/106). Among all ICC cases, squamous cell carcinoma was diagnosed in the majority of women (81.6% [80/98]). HPV prevalence among ICC cases was 84.7% (83/98). The HPV types most commonly detected in ICC cases with single HPV infection (98.8% [82/83]) were HPV-16 (67.3%) and HPV-18 (9.2%). Infection with multiple HPV types was recorded in a single case (co-infection of HPV-16 and HPV-59).ConclusionsHPV was prevalent in most women with ICC in Sri Lanka; HPV-16 and HPV-18 were the predominantly detected HPV types. An effective prophylactic vaccine against the most prevalent HPV types may help to reduce the burden of ICC disease.

show abstract

Section: Discussioncontrasting

confidence: 85%

Section: Discussionsupporting

confidence: 75%

Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka

et al. 2014

View full text Add to dashboard Cite

show abstract

“…• Currently, data on HPV-type prevalence from Bangladesh, Sri Lanka, and Nepal are lacking since there are no comprehensive formal screening programs in these countries. One study, in Sri Lanka, however, showed that 11 of 15 cases of squamous cell cancer of the cervix contained HPV-16 [23,31].…”

Section: Mozambiquementioning

confidence: 92%

Worldwide Impact of the Human Papillomavirus Vaccine

Hakim

Dinh

2009

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Nearly 500,000 new cases of cervical cancer and 274,000 cervical cancer deaths are occurring worldwide each year. Approximately 80% of the 500,000 new cases occur in developing countries and this percentage is expected to increase to 90% by 2020. In developing countries, cervical cancer tends to affect relatively young poor women and is the single largest cause of years of life lost to cancer, since screening and treatment programs, and health care, in general, are relatively inaccessible to these women. Each 5-year delay in vaccinating women against HPV may lead to the deaths of 1.5 to 2 million women from cervical cancer in developing countries. The high efficacy of the two available cervical cancer vaccines and their proven ability to reduce the incidence of cervical cancer precursor lesions offer hope that the vaccine will have enormous worldwide impact and may dramatically reduce the cervical cancer burden. The current vaccines protecting against HPV-16 and HPV-18 may prevent up to 70% of new cervical cancers. Vaccine cross-reactivity for HPV-31, -33, -45, and -52 suggest that an even higher percentage of cervical cancers might be prevented with its use. Currently, the prohibitive cost of the vaccine precludes its widespread implementation. Cooperation between governments, international health organizations, and the vaccine industry is needed to overcome this significant barrier so that women are no longer denied a potentially life-saving advance. Worldwide HPV vaccination and cervical cancer screening should be made an international priority.

show abstract

“…A recently completed community‐based study of 2000 ever‐married women aged between 20 and 59 years (mean 38 years, median 36 years) in the Gampaha (north of Colombo) district of Sri Lanka showed, via a combination of PCR testing and Papanicolaou (Pap) smears, a prevalence of 3.3% of cervico‐vaginal HPV infection overall and a prevalence of 3.1% of cervico‐vaginal HPV infection among women with normal cervical cell cytology [8]. In addition, there have been 2 hospital‐based studies evaluating cervical cancer: in the first [9], 15 patients with cervical squamous cell carcinoma showed a HPV positivity rate of 93.3% (HPV 16 in 11 cases [73.7%]; HPV 18 DNA in 3 cases [20%]); in the second [10], 40 patients diagnosed with cervical cancer showed a HPV positivity of 80% (HPV 16 in 29 cases [91%]; HPV 18 DNA in 2 cases [6%]).…”

Section: Introductionmentioning

confidence: 99%

Distribution of human papillomavirus genotypes in archival cervical tissue from women with cervical cancer in urban Sri Lanka

Samarawickrema

Tabrizi

Hewavisenthi

et al. 2011

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

PCR detection and typing of human papilloma virus DNA in squamous carcinoma of the cervix in a cohort of Sri Lankan women

Cited by 7 publications

References 0 publications

Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka

Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka

Worldwide Impact of the Human Papillomavirus Vaccine

Distribution of human papillomavirus genotypes in archival cervical tissue from women with cervical cancer in urban Sri Lanka

Contact Info

Product

Resources

About